 | Up a level |
Didden, EM; Ruffieux, Y; Hummel, N; Efthimiou, O; Reichenbach, S; Gsteiger, Sandro; Finckh, Axel; Fletcher, Christine; Salanti, G; Egger, Matthias; Work Package, IMI GetReal (2018). Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis. Medical decision making, 38(6), pp. 719-729. Sage Publications 10.1177/0272989X18775975
Kilcher, G; Didden, E; Hummel, N; Egger, M (November 2015). Characteristics of Patients Starting Biologic Treatments for Rheumatoid Arthritis in The Real World: Systematic Review. Value in health, 18(7), A657-A658. Elsevier 10.1016/j.jval.2015.09.2379
Hummel, N; Gsteiger, S (November 2015). Disease Progression In Rheumatoid Arthritis: Key Element for Cost-Effectiveness Modelling. Value in health, 18(7), A704-A705. Elsevier 10.1016/j.jval.2015.09.2642
